[go: up one dir, main page]

AR056884A1 - Compuestos biciclicos fusionados inhibidores de mtor - Google Patents

Compuestos biciclicos fusionados inhibidores de mtor

Info

Publication number
AR056884A1
AR056884A1 ARP060105058A ARP060105058A AR056884A1 AR 056884 A1 AR056884 A1 AR 056884A1 AR P060105058 A ARP060105058 A AR P060105058A AR P060105058 A ARP060105058 A AR P060105058A AR 056884 A1 AR056884 A1 AR 056884A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
aryl
optionally substituted
nr313c
Prior art date
Application number
ARP060105058A
Other languages
English (en)
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of AR056884A1 publication Critical patent/AR056884A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Son inhibidores de mTOR y son utiles en el tratamiento del cáncer. Reivindicacion 1: Un compuesto representado por la formula (1), o una sal aceptable para uso farmacéutico del mismo, donde, X1, y X2 son cada uno independientemente N o C-(E1)aa; X5 es N, C-(E1)aa, o N-(E1)aa; X3, X4, X6, y X7 son cada uno independientemente N o C; donde al menos uno de X3, X4, X5, X6 y X7 es independientemente N o N-(E1)aa; es alquilo C0-10, cicloalquilo C3-10, aminometilcicloalquilo C3-10, bicicloalquilo C5- 10, arilo, heteroarilo, aralquilo, heteroaralquilo, heterociclilo o heterobicicloalquilo, cualquiera de los cuales se sustituye opcionalmente con uno o más sustituyentes G11 independientes; Q1 es A(R1)mB(W)n o B(G11)nA(Y)m; A y B son respectivamente, anillos aromáticos o heteroaromáticos de 5 y 6 miembros, fusionados para formar un sistema heteroaromático de 9 miembros con la salvedad de 5-benzo[b]furilo y 3-indolilo; y con la salvedad de 2-indolilo, 2-benzoxazol, 2-benzotiazol, 2-benzimidazolilo, 4-aminopirrolpirimidin-5-ilo, 4-aminopirrolpirimidin-6-ilo y derivados de 7-deaza-7-adenosinilo cuando X1 y X5 son CH, X3, X6 y X7 son C, y X2 y X4 son N; o Q1 es A(R1)mA(Y)m, donde cada A es el mismo anillo o un anillo diferente aromático o heteroaromático de 5 miembros y los dos se fusionan para formar un sistema heteroaromático de 8 miembros; R1 es independientemente, hidrogeno, -N(alquil C0-8)(alquilo C0-8), hidroxilo, halogeno, oxo, arilo (sustituido opcionalmente por 1 o más grupos R31), hetarilo (sustituido opcionalmente por 1 o más grupos R31), alquilo C1-6, -alquil C0-8-cicloalquilo C3-8, -alquil C0-8-NR311S(O)0-2R321, -alquil C0-8-NR311S(O)0-2NR321R331, -alquil C0-8-S(O)0-2NR311R321, -alquil C0-8-NR311COR321, - alquil C0-8-NR311CO2R321, -alquil C0-8-NR311CONR321R331, -alquil C0-8-CONR311R321, -alquil C0-8CON(R311)S(O)0-2R321, -alquil C0-8-CO2R311, -alquil C0-8-S(O)0-2R311, -alquil C0-8-O-alquilo C1-8, -alquil C0-8-O-alquil C0-8-cicloalquilo C3-8, -alquil C0-8-O-alquilheterociclilo C0-8, -alquil C0-8-O-alquilarilo C0-8, -alquil C0-8-arilo, -alquil C0-8-hetarilo, -alquil C0-8-heterociclilo, -alquil C0-8-O-alquilhetarilo C0-8, -alquil C0-8-S-alquilo C0-8, -alquil C0-8-S-alquil C0-8-cicloalquilo C3-8, - alquil C0-8-S-alquilheterociclilo C0-8, -alquil C0-8-S-alquilarilo C0-8, -alquil C0-8-S-alquilhetarilo C0-8, -alquil C0-8-N(R311)-alquilo C0-8, -alquil C0-8-N(R311)-alquil C0-8-cicloalquilo C3-8, -alquil C0-8-N(R311)-alquilheterociclilo C0-8, - alquil C0-8-N(R311)-alquilarilo C0-8, -alquil C0-8-N(R311)-alquilhetarilo C0-8, -alquil C0-8-NR311R321, -alquenilo C2-8, -alquinilo C2-8, NO2, CN, CF3, OCF3, OCHF2 siempre que Q1 no sea N-metil-2-indolilo, N(fenilsulfonil)-2-indolilo o N-ter- butoxicarbonilo; W es independientemente hidrogeno, -N(alquil C0-8)(alquilo C0-8), hidroxilo, halogeno, oxo, arilo (sustituido opcionalmente por 1 o más grupos R31), hetarilo (sustituido opcionalmente por 1 o más grupos R31), alquilo C1-6, -alquil C0-8-cicloalquilo C3-8, -alquil C0-8-NR312S(O)0-2R322, -alquil C0-8-NR311S(O)0-2NR321R331, -alquil C0-8-NR311CO2R321, -alquil C0-8-CON(R311)S(O)0-2R321, -alquil C0-8-S(O)0-2NR312R322, -alquil C0-8-NR312COR322, -alquil C0-8-NR312CONR322R332, -alquil C0-8-CONR312R322, -alquil C0-8-CO2R312, -alquil C0-8-S(O)0-2R312, -alquil C0-8-O-alquilo C1-8, -alquil C0-8-O-alquilciclilo C0-8, -alquil C0-8-O-alquilheterocicloalquilo C0-8, -alquil C0-8-O-alquilarilo C0-8, -alquilarilo C0-8, -alquilhetarilo C0-8, -alquilheterociclilo C0-8, -O-arilo, -alquil C0-8-O-alquilhetarilo C0-8, -alquil C0-8-S-alquilo C0-8, -alquil C0-8-S-alquil C0-8-cicloalquilo C3-8, -alquil C0-8-S-alquiIheterocicIoaIquilo C0-8, -alquil C0-8-S-alquilarilo C0-8, -alquil C0-8-S- alquilhetarilo C0-8, -alquil C0-8-N(R312)-alquilo C0-8, -alquil C0-8-N(R312)-alquil C0-8-cicloalquilo C3-8, -alquil C0-8-N(R312)-alquilheterocicloalquilo C0-8, -alquil C0-8-N(R312)-alquilarilo C0-8, -alquil C0-8-N(R312)-alquilhetarilo C0-8, alquil C0-8-NR312R322, -alquenilo C2-8, -alquinilo C2-8, NO2, CN, CF3, OCF3, OCHF2 siempre que no sea 4-benciloxi-2-indolilo; Y es independientemente hidrogeno, -N(alquil C0-8)(alquilo C0-8), hidroxilo, halogeno, oxo, arilo (sustituido opcionalmente por 1 o más grupos R31), hetarilo (sustituido opcionalmente por 1 o más grupos R31), alquilo C0-6, -alquil C0-8-cicloalquilo C3-8, -alquil C0-8-NR311S(O)0-2R321, -alquil C0-8-NR311S(O)0-2NR321R331, -alquil C0-8-NR311CO2R321, -alquil C0-8-CON(R311)S(O)0- 2R321, -alquil C0-8-S(O)0-2NR311R321, -alquil C0-8-NR311COR321, -alquil C0-8-NR311CONR321R331, -alquil C0-8-CONR311R321, -alquil C0-8-CO2R311, -alquil C0-8-S(O)0-2R311, -alquil C0-8-O-alquilo C1-8, -alquil C0-8-O-alquil C0-8-cicloalquilo C3-8, - alquil C0-8-O-alquilheterocicloalquilo C0-8, -alquil C0-8-O-alquilarilo C0-8, -alquilarilo C0-8, -alquilhetarilo C0-8, -alquilheterociclilo C0-8, -alquil C0-8-O-alquilhetarilo C0-8, -alquil C0-8-S-alquilo C0-8, -alquil C0-8-S-alquil C0-8- cicloalquilo C3-8, -alquil C0-8-S-alquilheterocicloalquilo C0-8, -alquil C0-8-S-alquilarilo C0-8, -alquil C0-8-S-alquilhetarilo C0-8, -alquil C0-8-N(R311)-alquilo C0-8, -alquil C0-8-N(R311)-alquil C0-8-cicloalquilo C3-8, -alquil C0-8-N(R311)- alquilheterocicloalquilo C0-8, -alquil C0-8-N(R311)-alquilarilo C0-8, -alquil C0-8N(R311)-alquilhetarilo C0-8, -alquil C0-8-NR311R321, -alquenilo C2-8, -alquinilo C2-8, NO2, CN, CF3, OCF3, OCHF2 siempre que no sea 2-carboxi-5- benzo[b]tiofenilo; G11 es halo, oxo, -CF3, -OCF3, -OR312, -NR312R322, -C(O)R312, -(O)cicloalquilo C3-8, -CO2-cicloalquilo C3-8, -CO2R312, -C(=O)NR312R322, -NO2, -CN, -S(O)0-2R312, -SO2NR312R322, NR312(C=O)R322, NR312C(=O)OR322, NR312C(=O)NR322R332, NR312S(O)0-2R322, - C(=S)OR312, -C(=O)SR312, -NR312C(=NR322)NR332R341, -NR312C(=NR322)OR332, -NR312C(=NR322)SR332, -OC(=O)OR312, -OC(=O)NR312R322, -OC(=O)SR312, -SC(=O)OR312, -SC(=O)NR312R322, -P(O)OR312OR322, alquilideno C1-10, alquilo C0-10, alquenilo C2-10, alquinilo C2-10, -alcoxi C1-10-alquilo C1-10, -alcoxi C1-10-alquenilo C2-10, -alcoxi C1-10-alquinilo C2-10, -alquiltio C1-10-alquilo C1-10, -alquiltio C1-10-alquenilo C2-10, -alquiltio C1-10-alquinilo C2-10, cicloalquilo C3-8, cicloalquenilo C3-8, - cicloalquil C3-8-alquilo C1-10, -cicloalquenil C3-8-alquilo C1-10, -cicloalquil C3-8-alquenilo C2-10, -cicloalquenil C3-8-alquenilo C2-10, -cicloalquil C3-8-alquinilo C2-10, -cicloalquenil C3-8-alquinilo C2-10, -heterociclil-alquilo C0-10, - heterociclil-alquenilo C2-10 o -heterociclil-alquinilo C2-10, cualquiera de los cuales está sustituido opcionalmente por uno o más sustituyentes independientes halo, oxo, -CF3, -OCF3, -OR313, -NR313R323, -C(O)R313, -CO2R313, -C(=O)NR313R323, -NO2, - CN, -S(O)0-2R313, -SO2NR313R323, -NR313C(=O)R323, -NR313C(=O)OR323, -NR313C(=O)NR323R333, -NR313S(O)0-2R323, -C(=S)OR313, -C(=O)SR313, -NR313C(=NR323)NR333R342, -NR313C(=NR323)OR333, -NR313C(=NR323)SR333, -OC(=O)OR333, -OC(=O)NR313R323, - OC(=O)SR313, -SC(=O)OR313, -P(O)OR313OR323 o -SC(=O)R313R323; o G11 es aril-alquilo C0-10, aril-alquenilo C2-10, aril-alquinilo C2-10, hetarilalquilo C0-10, hetaril-alquenilo C2-10, o hetaril-alquinilo C2-10, donde el punto de union es desde la izquierda o la derecha segun lo escrito, donde cualquiera de los cuales está sustituido opcionalmente por uno o más sustituyentes independientes halo, -CF3, -OCF3, -OR313, -NR313R323, -C(O)R313, -CO2R313, -C(=O)NR313R323, -NO2, -CN, -S(O)0-2R313, - SO2NR313R323, -NR313C(=O)R323, -NR313C(=O)OR323, -NR313C(=O)NR323R333, -NR313S(O)0-2R323, -C(S)OR313, -C(O)SR313, -NR323C(=NR313)NR333R342, -NR313C(=NR323)OR333, -NR313C(=NR323)SR333, -OC(=O)OR313, -OC(=O)NR313R323, -OC(=O)SR313, -P(O)OR313OR323, o - SC(=O)NR313R323 siempre que G11 no sea N-CH2CO2H cuando R3 es 4-piperidinilo; R31, R32, R33, R311, R321, R331, R312, R322, R332, R341, R313, R323, R333, y R342, en cada caso, es independientemente alquilo C0-8 sustituido opcionalmente por un sustituyente arilo, heterociclilo o hetarilo o alquilo C0-8 sustituido opcionalmente por 1-6 sustituyentes independientes halo, -CON(alquil C0-8)(alquilo C0-8), -CO(alquilo C0-8), -O-alquilo C0-8, -O-arilo, -O-hetarilo, -O-heterociclilo, -S(O)0- 2arilo, -S(O)0-2hetarilo, -S(O)0-2heterociclilo, -S(O)0-2alquilo C0-8, -N(alquil C0-8)(alquilo C0-8), -N(alquil C0-8)CON(alquil C0-8)(alquilo C0-8), -N(alquil C0-8)CO(alquilo C1-8), -N(alquil C0-8)CO(cicloalquilo C3-8), -N(alquil C0-8)CO2(alquilo C1- 8), S(O)1-2N(alquil C0-8)(alquilo C0-8), -NR11S(O)1-2(alquilo C0-8), -CON(cicloalquil C3-8)(cicloalquilo C3-8), -CON(alquil C0-8)(cicloalquilo C3-8), -N(cicloalquil C3-8)CON(alquil C0-8)(alquilo C0-8), -N(cicloalquil C3-8)CON(cicloalquil C3- 8)(alquilo C0-8), -N(alquil C0-8)CON(cicloalquil C3-8)(alquilo C0-8), -N(alquil C0-8)CO2(cicloalquilo C3-8), -N(cicloalquil C3-8)CO2(cicloalquilo C3-8), S(O)1-2N(alquil C0-8)(cicloalquilo C3-8), -NR11S(O)1-2(cicloalquilo C3-8), alquenilo C2-8, alquinilo C2-8, CN, CF3, OH, o arilo sustituido opcionalmente; de manera que uno de los anteriores grupos arilo, heterociclilo, hetarilo, alquilo o cicloalquilo se pueden sustituir opcional e independientemente por -N(alquil C0-8)(alquilo C0-8), hidroxilo, halogeno, oxo, arilo, hetarilo, alquilo C0-6, -alquilciclilo C0-8, -alquil C0-8-N(alquil C0-8)-S(O)0-2-(alquilo C0-8), -alquil C0-8-S(O)0-2-N(alquil C0-8)(alquilo C0-8), -alquil C0-8-N(alquil C0-8)CO(alquilo C0-8), -alquil C0-8-N(alquil C0-8)CO-N(alquil C0-8)(alquilo C0-8), -alquil C0-8-CO-N(alquil C0-8)(alquilo C0-8), -alquil C1-8-CO2-(alquilo C0-8), -alquil C0-8-S(O)0-2-(alquilo C0-8), -alquil C0-8-O-alquilo C1-8, -alquil C0-8-O-alquilciclilo C0-8, -alquil C0-8-O- alquilheterociclilo C0-8, -alquil C0-8-O-alquilarilo C0-8, -alquil C0-8-O-alquilhetarilo C0-8, -alquil C0-8-S-alquilo C0-8, -alquil C0-8-S-alquilciclilo C0-8, -alquil C0-8-S-alquilheterociclilo C0-8, -alquil C0-8-S-alquilarilo C0-8, -alquil C0-8-S- alquilhetarilo C0-8, -alquil C0-8-N(alquil C0-8)-alquilo C0-8, -alquil C0-8N(alquil C0-8)-alquilciclilo C0-8, -alquil C0-8-N(alquil C0-8)-alquilheterocicl
ARP060105058A 2005-11-17 2006-11-17 Compuestos biciclicos fusionados inhibidores de mtor AR056884A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73758105P 2005-11-17 2005-11-17
US85424706P 2006-10-25 2006-10-25

Publications (1)

Publication Number Publication Date
AR056884A1 true AR056884A1 (es) 2007-10-31

Family

ID=38066461

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105058A AR056884A1 (es) 2005-11-17 2006-11-17 Compuestos biciclicos fusionados inhibidores de mtor

Country Status (25)

Country Link
US (6) US7700594B2 (es)
EP (3) EP2325186B1 (es)
JP (2) JP5335432B2 (es)
KR (1) KR20080078668A (es)
CN (2) CN101316845A (es)
AR (1) AR056884A1 (es)
AT (1) ATE507227T1 (es)
AU (1) AU2006316605B2 (es)
BR (1) BRPI0618622A2 (es)
CA (1) CA2630271C (es)
DE (1) DE602006021608D1 (es)
DK (1) DK1951724T3 (es)
EA (1) EA015463B1 (es)
ES (2) ES2436877T3 (es)
HR (1) HRP20110553T1 (es)
IL (1) IL191532A0 (es)
MY (1) MY148491A (es)
NZ (1) NZ569050A (es)
PL (2) PL1951724T3 (es)
PT (2) PT1951724E (es)
RS (1) RS51843B (es)
SI (1) SI1951724T1 (es)
TW (1) TWI382028B (es)
WO (1) WO2007061737A2 (es)
ZA (1) ZA200804237B (es)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305682A1 (en) 2004-04-02 2011-04-06 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2006112549A1 (ja) * 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited 縮合複素環化合物
RS51843B (sr) * 2005-11-17 2012-02-29 Osi Pharmaceuticals Llc. KONDENZOVANI BICIKLIČNI m TOR INHIBITORI
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
TW201307354A (zh) * 2005-12-29 2013-02-16 Abbott Lab 蛋白質激酶抑制劑
WO2007087395A2 (en) * 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
US7651687B2 (en) 2006-03-13 2010-01-26 Osi Pharmaceuticals, Inc. Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
MX2008012928A (es) 2006-04-04 2009-03-06 Univ California Antagonistas de pi3-cinasa.
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
CN101730700A (zh) * 2007-05-09 2010-06-09 雅培制药有限公司 用作蛋白激酶抑制剂的稠合杂环化合物
WO2008141140A1 (en) * 2007-05-09 2008-11-20 Abbott Laboratories Condensed heterocyclic compounds as inhibitors of protein kinases
WO2008148074A2 (en) * 2007-05-24 2008-12-04 Research Foundation Of State University Of New York Inhibitors of mtor and methods of treatment using same
JP2010532756A (ja) * 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
ES2647163T3 (es) 2008-01-04 2017-12-19 Intellikine, Inc. Derivados de isoquinolinona sustituidos con una purina útiles como inhibidores de la PI3K
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
NZ587271A (en) * 2008-02-06 2012-03-30 Novartis Ag Pyrrolo[2,3-d]pyrimidines containing a 7h-pyrrolo[2,3-d]pyrimidin-2-yl core and use thereof as tyrosine kinase inhibitors
WO2009111547A1 (en) * 2008-03-04 2009-09-11 Wyeth 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
EP2252293B1 (en) * 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
BRPI0910232A2 (pt) * 2008-03-19 2015-09-29 Osi Pharm Inc formas de sais inibidores do mtor
US8685995B2 (en) * 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
CA2740885C (en) 2008-10-16 2018-04-03 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5487214B2 (ja) 2008-12-19 2014-05-07 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
CA2761389A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP2417138B1 (en) * 2009-04-09 2019-11-27 Merck Sharp & Dohme Corp. Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors
EP2421837A1 (en) 2009-04-20 2012-02-29 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
WO2011005909A2 (en) * 2009-07-09 2011-01-13 Osi Pharmaceuticals, Inc. Process for substituted 3-amino-5-oxo-4,5-dihydro-[1,2,4]triazines
AU2010284254B2 (en) 2009-08-17 2015-09-17 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2011041152A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
US9765037B2 (en) 2010-01-28 2017-09-19 University Of Washington Through Its Center For Commercialization Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
EP2528919B1 (en) * 2010-01-28 2016-11-02 University of Washington Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
KR101942212B1 (ko) 2010-02-03 2019-01-24 시그날 파마소티칼 엘엘씨 Ｔｏｒ 키나제 억제자에 대한 민감성 예측 바이오마커로서 ｌｋｂ1 돌연변이의 동정
WO2011112666A1 (en) 2010-03-09 2011-09-15 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20130005651A1 (en) 2010-03-11 2013-01-03 Yeda Research And Development Co. Ltd. Death associated protein 1 variants and use thereof for modulating autophagy
CN102869358B (zh) 2010-04-13 2016-03-23 诺华股份有限公司 用于治疗癌症的包含细胞周期蛋白依赖性激酶4或细胞周期蛋白依赖性激酶6(CDK4/6)抑制剂和mTOR抑制剂的组合
WO2011141713A1 (en) * 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
KR20180080358A (ko) 2011-01-10 2018-07-11 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
CA2828483A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kinase inhibitors and uses thereof
EP2681218A1 (en) 2011-02-23 2014-01-08 Pfizer Inc IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
ES2950569T3 (es) 2011-07-19 2023-10-11 Merck Sharp & Dohme (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-2-metoxi-n-(piridin-2-il)benzamida como inhibidor de la Btk
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2841887A1 (en) * 2011-07-19 2013-01-24 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2013019927A1 (en) 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for lkb1 status
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
CA2862981C (en) 2011-12-15 2020-02-25 Bayer Pharma Aktiengesellschaft Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer
ES2581065T3 (es) 2012-02-23 2016-08-31 Bayer Intellectual Property Gmbh Benzotienil-pirrolotriazinas sustituidas y usos de las mismas
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103374001B (zh) * 2012-04-19 2015-10-28 山东轩竹医药科技有限公司 咪唑并三嗪类mTOR抑制剂
CN103374021B (zh) * 2012-04-21 2015-10-28 通化济达医药有限公司 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014052669A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
DK2914296T4 (da) 2012-11-01 2022-01-03 Infinity Pharmaceuticals Inc Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer
AU2014236135A1 (en) 2013-03-14 2015-09-10 Thomas Jefferson University Androgen receptor down-regulating agents and uses thereof
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
SG11201508302PA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
KR102240356B1 (ko) 2013-04-17 2021-04-14 시그날 파마소티칼 엘엘씨 Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
US9359364B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one
HK1221144A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
SG10201801965RA (en) 2013-04-17 2018-04-27 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
EP2986298A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Treatment of cancer with dihydropyrazino-pyrazines
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
US9518026B2 (en) 2013-05-20 2016-12-13 University Of Washington Through Its Center For Commercialization 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum
CN105407892B (zh) 2013-05-29 2019-05-07 西格诺药品有限公司 一种化合物的药物组合物、其固体形式及它们的使用方法
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
EP3033088A4 (en) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2900806T3 (es) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos
JP2016540053A (ja) 2013-12-05 2016-12-22 アセルタ ファーマ ビー．ブイ． Ｐｉ３ｋ阻害剤とｂｔｋ阻害剤の治療的組み合わせ
CA2935167C (en) 2014-01-16 2022-02-22 Musc Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
JP6855243B2 (ja) 2014-01-24 2021-04-07 エイアイ・セラピューティクス・インコーポレーテッド 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
MX2016015569A (es) 2014-06-02 2017-04-25 Children´S Medical Center Corp Metodos y composiciones para inmunomodulacion.
US10987322B2 (en) 2014-06-06 2021-04-27 Flexus Biosciences, Inc. Immunoregulatory agents
TW201613644A (en) 2014-06-17 2016-04-16 Acerta Pharma Bv Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor
HRP20211813T1 (hr) 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10023576B2 (en) 2014-10-22 2018-07-17 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
ES2807785T3 (es) 2014-10-22 2021-02-24 Bristol Myers Squibb Co Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
UY36391A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
CN107205970A (zh) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 免疫调节剂
JP6768682B2 (ja) 2014-11-07 2020-10-14 エイアイ・セラピューティクス・インコーポレーテッド メラノーマの処置に使用するためのアピリモド
EP3581184B1 (en) 2014-11-07 2021-02-24 AI Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
ES2792036T3 (es) * 2014-11-14 2020-11-06 Nerviano Medical Sciences Srl Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de cinasa
WO2016106623A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016132998A1 (ja) * 2015-02-19 2016-08-25 Jnc株式会社 ベンゾチオフェンを有する液晶性化合物、液晶組成物および液晶表示素子
US20180078561A1 (en) 2015-03-31 2018-03-22 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
RS60411B1 (sr) 2015-07-02 2020-07-31 Acerta Pharma Bv Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
JP6980649B2 (ja) 2015-09-14 2021-12-15 インフィニティー ファーマシューティカルズ， インコーポレイテッド イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
CN105732460A (zh) * 2016-02-03 2016-07-06 常州工程职业技术学院 一种吲哚类化合物的合成方法
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
SMT202300480T1 (it) * 2016-03-28 2024-01-10 Incyte Corp Composti di pirrolotriazina come inibitori di tam
IL297192A (en) 2016-04-15 2022-12-01 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
DK3442535T3 (da) 2016-04-15 2022-09-05 Cancer Research Tech Ltd Heterocykliske stoffer som as ret-kinase-hæmmere
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
KR20200012876A (ko) * 2017-05-02 2020-02-05 레볼루션 메디슨즈, 인크. mTOR 억제제로서의 파라마이신 유사체
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
KR102707041B1 (ko) * 2017-08-15 2024-09-19 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 Fgfr 억제제 및 그의 의학적 용도
TWI821200B (zh) 2017-09-27 2023-11-11 美商英塞特公司 Tam抑制劑之鹽
KR20200077518A (ko) 2017-09-27 2020-06-30 에이아이 테라퓨틱스, 인코포레이티드 Hsp90 억제제에 관한 치료 방법
FR3075794A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075795A1 (fr) * 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
EA202091777A1 (ru) * 2018-01-26 2020-10-14 Бристол-Маерс Сквибб Компани Аминопирролотриазины в качестве ингибиторов киназы
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
MX2020011565A (es) 2018-05-01 2021-01-29 Revolution Medicines Inc Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
LT3813946T (lt) 2018-06-15 2024-07-10 Janssen Pharmaceutica Nv Rapamicino analogai ir jų panaudojimas
PT3813800T (pt) 2018-06-29 2025-06-06 Incyte Corp Formulações de um inibidor de axl/mer
SG11202013216RA (en) 2018-07-05 2021-01-28 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
AU2020214188A1 (en) * 2019-01-31 2021-07-15 Bayer Aktiengesellschaft The monohydrate of rogaratinib hydrochloride and solid states thereof
CN115209897A (zh) 2019-12-05 2022-10-18 安纳库利亚治疗公司 雷帕霉素类似物及其用途
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
AU2022224567A1 (en) 2021-02-16 2023-08-24 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles based on amphiphilic peptides
WO2023288046A1 (en) 2021-07-15 2023-01-19 President And Fellows Of Harvard College Compositions and methods relating to cells with adhered particles
JP2025522296A (ja) 2022-05-25 2025-07-15 レヴォリューション・メディスンズ，インコーポレイテッド ｍＴＯＲ阻害剤によりがんを処置する方法
US20230381190A1 (en) * 2022-05-27 2023-11-30 Avalo Therapeutics, Inc. Methods and Treatment for Complex Lymphatic Malformations
US20240269269A1 (en) 2022-10-25 2024-08-15 Vaccitech North America, Inc. Self-Assembling Nanoparticles
CN118754873B (zh) * 2024-06-27 2025-03-07 广东医科大学 一种环丁烷吲哚衍生物及其制备方法和应用
CN118994167B (zh) * 2024-08-09 2025-09-12 南京健康产业研究院 一种咪唑并[1,5-a]吡嗪类抗肿瘤化合物及其制备方法和应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
PT783505E (pt) 1994-09-29 2001-08-30 Novartis Ag Pirrolo¬2,3-d|pirimidinas e sua utilizacao
US6071891A (en) * 1996-11-22 2000-06-06 Regents Of The University Of Minnesota Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition
IL131582A0 (en) 1997-03-19 2001-01-28 Basf Ag Pyrrolo [2,3d] pyrimidines and their use as tyrosine kinase inhibitors
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
BR0014073A (pt) 1999-09-17 2002-07-16 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapêuticos
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
MXPA02002938A (es) 1999-09-17 2004-12-06 Abbott Gmbh & Co Kg Inhibidores de cinasa como agentes agentes terapeuticos.
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2002333524A1 (en) 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US20040209930A1 (en) * 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
EP1594894A2 (en) 2003-02-18 2005-11-16 Whitehead Institute For Biomedical Research Mtor kinase-associated proteins
BRPI0415395A (pt) * 2003-10-15 2006-12-12 Osi Pharm Inc composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
US7169918B2 (en) 2003-10-27 2007-01-30 Genelabs Technologies, Inc. Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
WO2005054268A1 (en) 2003-10-27 2005-06-16 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
BRPI0416656A (pt) 2003-11-17 2007-01-16 Pfizer Prod Inc compostos de pirrolopirimidina úteis no tratamento do cáncer
US7572914B2 (en) * 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2305682A1 (en) 2004-04-02 2011-04-06 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
EP2322215A3 (en) * 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
AR053090A1 (es) * 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
EP1831225A2 (en) * 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
WO2006081425A1 (en) 2005-01-28 2006-08-03 Whitehead Institute For Biomedical Research Phosphorylation and regulation of akt/pkb by the rictor-mtor complex
CA2626456C (en) 2005-10-18 2018-01-09 George Mason Intellectual Properties, Inc. Mtor pathway theranostic
JP5116687B2 (ja) * 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
RS51843B (sr) * 2005-11-17 2012-02-29 Osi Pharmaceuticals Llc. KONDENZOVANI BICIKLIČNI m TOR INHIBITORI
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2007075554A2 (en) 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
TW201307354A (zh) 2005-12-29 2013-02-16 Abbott Lab 蛋白質激酶抑制劑
WO2007087395A2 (en) * 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
US7651687B2 (en) 2006-03-13 2010-01-26 Osi Pharmaceuticals, Inc. Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
WO2007126841A2 (en) 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
MX2008012928A (es) 2006-04-04 2009-03-06 Univ California Antagonistas de pi3-cinasa.
DE102006016426A1 (de) 2006-04-07 2007-10-11 Merck Patent Gmbh Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
WO2008070100A1 (en) 2006-12-05 2008-06-12 University Of South Florida Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
JP2010532756A (ja) * 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
EP2173338A1 (en) * 2007-07-06 2010-04-14 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy
JP2011500657A (ja) 2007-10-15 2011-01-06 アストラゼネカ アクチボラグ 組合せ０５９
BRPI0910232A2 (pt) * 2008-03-19 2015-09-29 Osi Pharm Inc formas de sais inibidores do mtor
WO2011005909A2 (en) 2009-07-09 2011-01-13 Osi Pharmaceuticals, Inc. Process for substituted 3-amino-5-oxo-4,5-dihydro-[1,2,4]triazines
EP2459191A1 (en) 2009-07-31 2012-06-06 OSI Pharmaceuticals, LLC Mtor inhibitor and angiogenesis inhibitor combination therapy
WO2011112666A1 (en) 2010-03-09 2011-09-15 OSI Pharmaceuticals, LLC Combination anti-cancer therapy

Also Published As

Publication number Publication date
WO2007061737A3 (en) 2007-12-06
CA2630271C (en) 2014-04-08
WO2007061737A2 (en) 2007-05-31
TW200801006A (en) 2008-01-01
CN102936250A (zh) 2013-02-20
AU2006316605B2 (en) 2012-04-26
ATE507227T1 (de) 2011-05-15
ZA200804237B (en) 2009-09-30
EA200801341A1 (ru) 2008-12-30
US8796455B2 (en) 2014-08-05
EA015463B1 (ru) 2011-08-30
KR20080078668A (ko) 2008-08-27
DK1951724T3 (da) 2011-08-15
CA2630271A1 (en) 2007-05-31
MY148491A (en) 2013-04-30
PT1951724E (pt) 2011-08-02
US7943767B2 (en) 2011-05-17
BRPI0618622A2 (pt) 2011-09-06
PL1951724T3 (pl) 2011-09-30
US20130165651A1 (en) 2013-06-27
HK1121158A1 (en) 2009-04-17
TWI382028B (zh) 2013-01-11
HRP20110553T1 (hr) 2011-09-30
US20110190496A1 (en) 2011-08-04
JP2009519222A (ja) 2009-05-14
IL191532A0 (en) 2008-12-29
US20070112005A1 (en) 2007-05-17
US8314111B2 (en) 2012-11-20
JP2010065049A (ja) 2010-03-25
CN102936250B (zh) 2014-07-09
EP1951724B1 (en) 2011-04-27
EP2385053B1 (en) 2013-10-02
EP2325186A3 (en) 2011-10-26
US20100099679A1 (en) 2010-04-22
JP5335432B2 (ja) 2013-11-06
DE602006021608D1 (de) 2011-06-09
EP2385053A3 (en) 2012-02-29
EP2385053A2 (en) 2011-11-09
NZ569050A (en) 2010-11-26
JP4491510B2 (ja) 2010-06-30
ES2365869T3 (es) 2011-10-11
US7923555B2 (en) 2011-04-12
PL2385053T3 (pl) 2014-05-30
EP2325186A2 (en) 2011-05-25
US7700594B2 (en) 2010-04-20
CN101316845A (zh) 2008-12-03
EP1951724A2 (en) 2008-08-06
US20090163468A1 (en) 2009-06-25
ES2436877T3 (es) 2014-01-07
SI1951724T1 (sl) 2011-09-30
US20110218183A1 (en) 2011-09-08
PT2385053E (pt) 2013-12-17
AU2006316605A1 (en) 2007-05-31
RS51843B (sr) 2012-02-29
EP2325186B1 (en) 2014-10-08

Similar Documents

Publication Publication Date Title
AR056884A1 (es) Compuestos biciclicos fusionados inhibidores de mtor
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
ECSP088431A (es) Derivados de pirazolo
AR062224A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa ns3 del virus de hepatitis c y composiciones farmaceuticas que los comprenden.
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
UY30499A1 (es) Derivados de amina utiles como agentes anticancerigenos
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR052863A1 (es) Compuestos de quinolina heteroaromaticos
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
AR071452A1 (es) Inhibidores de hsp90
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
AR049443A1 (es) Derivados de pirrolpiridinas
CO6190525A2 (es) Fosfoindoles enantiomericamente puros como inhibidores de vih
AR061666A1 (es) Derivados de bencimidazol, metodo de produccion de los mismos y preparaciones farmaceuticas que los contienen
PE20191647A1 (es) Acidos propionicos 3-sustituidos como inhibidores de la integrina alfa v
NO20083598L (no) Karbosykliske og heterosykliske arylsulfoner som inhibitorer av gamma-sekretase
AR058065A1 (es) Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas.
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal